GRB1L: A Protein Implicated in Neurodegenerative Disorders and Other Diseases

Target Name: GREB1L

NCBI ID: G80000

GREB1L

GRB1L: A Protein Implicated in Neurodegenerative Disorders and Other Diseases

GREB1L (GRB1L_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a key role in cellular signaling.

GRB1L is involved in a variety of physiological processes in the body, including modulating neurotransmitter signaling, regulating ion channels, and contributing to the regulation of inflammation. It is also involved in the development and progression of a variety of diseases, including neurodegenerative disorders, cardiovascular disease, and renal disease.

Due to its involvement in a wide range of physiological processes, GRB1L has been identified as a potential drug target. Studies have shown that inhibiting GRB1L activity has the potential to treat a variety of diseases, including neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

GRB1L is also a potential biomarker for a variety of diseases. For example, decreased levels of GRB1L have been associated with the development of neurodegenerative disorders, and increased levels of GRB1L have been observed in the brains of individuals with these disorders. Additionally, changes in GRB1L expression have been observed in a variety of diseases, including cardiovascular disease and renal disease.

In addition to its potential as a drug target and biomarker, GRB1L is also of interest due to its structural and functional similarities to other GPCR proteins.GRB1L and its close relatives, including GRB2 and GRB3, share a common structural domain and are involved in similar signaling pathways. This suggests that they may have similar functions and may be good candidates for drug targeting.

Furthermore, the study of GRB1L has also identified a potential negative regulator, called IDH, which plays a role in the regulation of GRB1L activity. This suggests that targeting the IDH pathway may be a potential strategy for treating GRB1L-related diseases.

In conclusion, GREB1L (GRB1L_HUMAN) is a protein that is expressed in various tissues of the human body and is involved in a variety of physiological processes. It is also involved in the development and progression of a variety of diseases, including neurodegenerative disorders, cardiovascular disease, and renal disease. As a result, it has been identified as a potential drug target and biomarker, and further research is needed to understand its full role in these processes and to develop effective treatments.

Protein Name: GREB1 Like Retinoic Acid Receptor Coactivator

Functions: Plays a major role in early metanephros and genital development

The "GREB1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GREB1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets